Consider Cardiovascular Benefits When Choosing a GLP-1 Agonist

Trulicity (dulaglutide) will be the third GLP-1 agonist to show CV benefits in some patients with type 2 diabetes.

It joins Ozempic (semaglutide) and Victoza (liraglutide). All three lower CV risk in type 2 patients with CV disease or at high CV risk.

Each of these meds also seems to slow progression to albuminuria...but none have been shown to delay dialysis.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote